OncRef

Clinical Trial: NCT04025541

Analysis of Circulating Tumor Markers in Blood

Status:

RECRUITING

Phase:

Not Applicable

Lead Sponsor:Institut du Cancer de Montpellier - Val d'Aurelle
Information Provided By:Institut du Cancer de Montpellier - Val d'Aurelle
Last Update Posted:2025-04-02

Study Overview

Brief Summary

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Official Title

Analysis of Circulating Tumor Markers in Blood

Conditions

Cancer, Breast Cancer, Sarcoma, Lung Cancers, Glioma, Colon Cancer

Intervention / Treatment

  • Biological: Blood sampling
  • Biological: Blood sampling C3
  • Biological: Blood sampling C4/7/10/13
  • Biological: Blood sampling C5
  • Biological: Blood sampling C6
  • Biological: Blood sampling C8
  • Biological: Blood sampling C9
  • Biological: Blood sampling C11 + FFPE
  • Biological: Blood sampling C12

Other Study ID Numbers

  • PROICM 2017-05 BAL

Start Date (Actual)

2018-05-29

Primary Completion Date (Estimated)

2026-05-29

Study Completion Date (Estimated)

2029-05-29

Enrollment (Estimated)

992

Study Type

Interventional

Phase

Not Applicable